Podcasts

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

How Recent Executive Orders Impact the Drug Pricing Landscape

Videos


In the first part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, describes the disparity in organizations utilizing supply-chain specific applications. 

Bridging the GenAI Adoption Gap in Supply Chain

Articles

The designation allows pharmacists to substitute it for Humira without prescriber approval (per state law), which expands patient access in the process.

FDA Grants Interchangeability Designation to Hadlima

This serialization system represents a business imperative that yields significant competitive advantages.

Serialization 2.0: Why It’s Time to Upgrade, and What’s at Stake

The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.

Mercalis and PharmaCord Officially Merge, Form Valeris

Vice President of Life Sciences at Kenco.

As this medical approach continues to become more widely adopted, the industry must adapt to help provide precise, compliant, temperature-controlled delivery of highly individualized treatments.

How the Rise of Personalized Medicine Impacts Life Sciences’ Logistics

In the final part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes best practices for balancing long-term pipeline sustainability with short-term financial returns.

A Balancing Act

Pharma Pulse 5/23/25: The Role of AI in Solving Clinical Trial Diversity and Access Challenges; FDA Advisors Unanimously Snub Pfizer's Talzenna in Broader Prostate Cancer Population

Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by real-time data.

Keeping Drug Supplies Available Means Pharmaceutical Organizations Must Move in Real-Time 

Bruce Leuchter, CEO, Neurvati, discusses the indispensable role of patient advocates—particularly in rare and serious disease drug development—in shaping trial design, site selection, and regulatory strategy.

News